UK Peptide Regulation 2026 — MHRA Position, POM Class, and Where the Lines Sit

UK peptide regulation has shifted materially over 2024–2026 — driven by the rapid clinical uptake of GLP-1 / GIP receptor agonists (Tirzepatide, Semaglutide), pressure on supply chains, public-facing advertising enforcement, and a more visible MHRA posture on borderline compounds. This article sits alongside the live framing in the UK regulation hub and the medical disclaimer; none of it is legal advice.

The baseline MHRA position

Under the Human Medicines Regulations 2012, a substance is a medicinal product if it is either (a) presented as having properties for treating or preventing disease (presentational limb) or (b) used by, or administered to, a human with a view to restoring, correcting or modifying physiological function by exerting pharmacological, immunological or metabolic action (functional limb).

The presentational limb is broad. A compound sold with the words "research use only" can still meet the definition of a medicinal product if the marketing and supply context presents it as a treatment — the label is not the legal status. See UK peptide law & the MHRA explained.

The vast majority of peptides discussed on PeptideStacks — BPC-157, TB-500, GHK-Cu, Epitalon, MOTS-c, Humanin, SS-31, Semax, Selank, Pinealon, Thymalin, KPV, LL-37 — have no UK marketing authorisation. They are not approved for human medicinal use, veterinary use, or any consumer indication.

These compounds can be lawfully purchased and held in the UK strictly for laboratory research. Importation, supply, or administration to humans or animals outside an approved clinical trial may engage the Medicines for Human Use (Clinical Trials) Regulations 2004 and may constitute a criminal offence. See: importation risks for peptides (UK), what 'research use only' means in the UK.

The GLP-1 / POM reclassification picture

Tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic) hold UK marketing authorisations as medicinal products and are prescription-only medicines (POM). They are also, in current MHRA enforcement priority, the most publicly-policed peptide-class POMs in the UK consumer advertising space.

The MHRA has issued public-facing warnings about advertising of prescription-only weight-loss medicines to the UK public, has actioned specific advertisers, and continues to work with the Advertising Standards Authority on cross-jurisdictional enforcement. See: POM advertising rules, weight-loss medicine advertising caution (UK).

Research-grade equivalents of these compounds — sold to laboratories without therapeutic claims and not in the licensed presentation — occupy an ambiguous regulatory space. The MHRA's published position is that research-use supply remains permissible only where supplier and end-user can demonstrate genuine research use; the borderline-product framework otherwise applies. See: borderline products — when peptides become medicinal.

Retatrutide is in late-stage clinical trials and does not yet hold UK marketing authorisation as of mid-2026. UK research-grade material is permissible for laboratory work; any presentation as a weight-loss product to the public would engage both POM-advertising rules and investigational-medicine restrictions.

Compounds approved elsewhere but not in the UK

Several peptides on this site hold marketing authorisations outside the UK without a parallel UK licence:

Tesamorelin (EGRIFTA / Egrifta SV) — FDA/EMA approved for HIV- associated lipodystrophy. UK availability is intermittent through the Specials route. See unlicensed medicines & 'Specials' explained.
PT-141 (bremelanotide / Vyleesi) — FDA-approved for HSDD in pre-menopausal women in the US; not authorised in the UK.
Cerebrolysin — approved as a medicinal product in several non-UK European jurisdictions (Austria, parts of central/eastern Europe). Not UK-licensed; importation requires Special Authorisation through the MHRA.
Thymosin α-1 (Zadaxin) — approved in parts of Asia and Latin America for chronic viral hepatitis; not UK-licensed.

We treat all of these as Grade B in our evidence grading methodology — the human evidence base exists, but the UK regulatory status is "unlicensed" or "Specials-only" rather than "approved."

Compounds under increased MHRA scrutiny

Active 2025–2026 enforcement priorities relevant to this site include:

GLP-1 weight-loss medicines — public-facing advertising, particularly on social media and via affiliate/influencer channels. The most enforcement activity of any class.
PT-141 / bremelanotide — public-facing UK advertising would breach POM rules. Research-grade material is permissible for laboratory work.
Melanotan II — long-standing enforcement target, with documented prosecutions of suppliers marketing it as a "tanning agent" to UK consumers. The MHRA has issued public-facing safety warnings about unauthorised tanning injections.
Cardarine, MK-677, SARMs — sometimes informally bundled with peptide research compounds in grey-market marketing. These are not peptides and have separate (and more restrictive) regulatory positions under drug-control law. PeptideStacks does not cover them.

Other frameworks that may apply

Beyond medicines law, peptides can engage:

WADA / UK Anti-Doping — many peptides are explicitly prohibited under the WADA Code in and out of competition. See peptides and sports anti-doping.
Veterinary Medicines Regulations 2013 — for animal-administration contexts.
ASA / CAP Code — for consumer advertising, including borderline cosmetic and wellness claims.
Misuse of Drugs Act 1971 and Psychoactive Substances Act 2016 for narrowly-defined compounds.

What this means for readers

PeptideStacks describes published evidence and the UK regulatory framing. We do not provide importation routes, sourcing guidance, or self-administration instructions. The regulatory environment in 2026 is materially different from 2024; for any specific compound, verify the current MHRA classification before any handling. For clinical questions, consult a registered prescriber — not a website.